Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma

Anti-programmed cell death-1 (anti-PD-1) therapies have shown a favorable efficacy and good tolerance for relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). However, there are limited data on long-term outcomes among patients with r/r cHL who achieve an objective response to anti-PD-1 th...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Weiping, Lin, Ningjing, Feng, Xinqin, Xie, Yan, You, Chong, Zhou, Xiaohua, Song, Yuqin, Zhu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509238/
https://www.ncbi.nlm.nih.gov/pubmed/37726266
http://dx.doi.org/10.1038/s41392-023-01600-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509238/
https://www.ncbi.nlm.nih.gov/pubmed/37726266
http://dx.doi.org/10.1038/s41392-023-01600-7

Ejemplares similares